inThought Approvability Index
The inThought Approvability Index (IAI) is a dynamic tool that assesses the progress of a drug candidate through clinical development. This tool can be used to evaluate strength of clinical data and trial design, benchmarked against historical parameters and the drug’s likelihood to maintain forward momentum.
How It Works
inThought analysts scrutinize all aspects of development (preclinical to current phase), validate hypotheses with key opinion leaders and investigators, and assign points for specific line items relating to safety, efficacy, tolerability and other factors.
Historical Approval Rates
Possible points total 100 upon drug approval and are allocated in each phase according to the historical approval rate of similar drugs, such that the current points of a drug relate to its probability of approval.
Current Approval Track
A letter grade is assigned and reflects the momentum of a drug candidate in its current phase, with “A” indicating significantly above average/likely to progress, “C” indicating average, and “F” indicating significantly below average/unlikely to progress.
inThought Approvability Index
The inThought Approvability Index (IAI) is a dynamic tool that assesses the progress of a drug candidate through clinical development. This tool can be used to evaluate strength of clinical data and trial design, benchmarked against historical parameters and the drug’s likelihood to maintain forward momentum.
How It Works
inThought analysts scrutinize all aspects of development (preclinical to current phase), validate hypotheses with key opinion leaders and investigators, and assign points for specific line items relating to safety, efficacy, tolerability and other factors.
Historical Approval Rates
Possible points total 100 upon drug approval and are allocated in each phase according to the historical approval rate of similar drugs, such that the current points of a drug relate to its probability of approval.
Current Approval Track
A letter grade is assigned and reflects the momentum of a drug candidate in its current phase, with “A” indicating significantly above average/likely to progress, “C” indicating average, and “F” indicating significantly below average/unlikely to progress.